Lamivudine plus adefovir combination therapy for lamivudine resistance in hepatitis-B-related hepatocellular carcinoma patients

BACKGROUND/AIMS: Lamivudine (LAM) plus adefovir (ADV) combination therapy has been accepted as one of the best treatments for LAM-resistant chronic hepatitis B (CHB). The aim of this study was to determine the efficacy of this combination therapy in hepatocellular carcinoma (HCC) patients. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Jeong Han, Ko, Soon Young, Choe, Won Hyeok, Kwon, So Young, Lee, Chang Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Association for the Study of the Liver 2013
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3796677/
https://www.ncbi.nlm.nih.gov/pubmed/24133665
http://dx.doi.org/10.3350/cmh.2013.19.3.273

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3796677/
https://www.ncbi.nlm.nih.gov/pubmed/24133665
http://dx.doi.org/10.3350/cmh.2013.19.3.273

Ejemplares similares